{"id":"W4387809547","doi":"10.1016/j.annonc.2023.10.087","title":"LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; Astellas Pharma; National Evidence-based Healthcare Collaborating Agency; Sanofi; AstraZeneca; Pfizer","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Oncology; Abiraterone; Homologous recombination; Internal medicine; Cancer research; Gene; Cancer; Androgen deprivation therapy; Genetics; Androgen receptor; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002491858,0.0003705546,0.001510846,0.0007381742,0.0001657874,0.001357396,0.0008308209,0.0005094167,0.001618134],"category_scores_gemma":[0.002309713,0.0002383519,0.001417229,0.001178111,0.0002914912,0.0006986983,0.0004270131,0.001936981,0.0004732318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001291413,"about_ca_system_score_gemma":0.001359297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001744455,"about_ca_topic_score_gemma":0.009855736,"domain_scores_codex":[0.9994381,0.000141825,0.0001088916,0.00007658047,0.0001774521,0.00005718582],"domain_scores_gemma":[0.9985822,0.0004941541,0.0004979296,0.00005187764,0.0002401687,0.0001335712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.003508833,0.0002774446,0.008540564,0.003946716,0.001300816,0.0001015769,0.0000771569,0.0008227098,0.002586485,0.0004694216,0.01656692,0.9618014],"study_design_scores_gemma":[0.01094568,0.01659021,0.2309625,0.0102089,0.01409876,0.005420594,0.0003000146,0.003284045,0.007204395,0.002488581,0.698298,0.000198324],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.07606324,0.8990888,0.001364509,0.007700808,0.0009614807,0.000260629,0.003035256,0.0002733028,0.01125199],"genre_scores_gemma":[0.3057911,0.6647332,0.00450579,0.01187649,0.001302634,0.0003239923,0.007096987,0.00008289486,0.004286938],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002491858,"threshold_uncertainty_score":0.01317841,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0732502613041532,"score_gpt":0.3629137136856987,"score_spread":0.2896634523815456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}